Measurement of cyclosporine a by a specific radioimmunoassay with a monoclonal antibody and 125I tracer

Lee, Sung C.; Brudzinski, Alice M.; Yasmineh, Joan L.; Johanson, Nancy J.; Ferber, Irene A.; Maas, Lori K.; Wong, Pui-Yuen; Keown, Paul; Orf, John W.

doi:10.1016/0009-9120(91)90168-e

Cited by 16 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These clinical and experimental observations, as well as the idiosyncratic behavior of each patient, may suggest that Tac-based immunosuppression can decrease the frequency of CAN and that Tac use could be also beneficial for patients with documented CAN under CsA. Therefore, switching from CsA to Tac has been proposed as safe and effective in patients with CsA intolerance, nephrotoxicity, or ongoing rejection (15)(16)(17)(18)(19)(20)(21).…”

mentioning

confidence: 92%

Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events

et al. 2005

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 92%

Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events

et al. 2005

View full text Add to dashboard Cite

show abstract

“…[92][93][94] There is a mean overestimate compared with HPLC of around 25% ( Although the CYCLO-Trac" SP kit uses the same monoclonal antibody as the original Sandimmunf-Kit, cross-reactivity with cyclosporin metabolites appears greater for the former assay, perhaps as a result of the different tracer or the secondary antibody precipitation step. Overestimation relative to HPLC is approximately twice that of the Sandimmun assay" and crossreactivity is greatest for metabolites AM9, AM4N and AMI, ranging from 2'2-15070, 1'7-4-4010 and 0·7 to 5'7070, respectively.Pv'"…”

Section: Min --mentioning

confidence: 99%

Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force

Holt¹,

Johnston

et al. 1994

Ann Clin Biochem

View full text Add to dashboard Cite

Additional key phrases: immunosuppressant drugs; analytical methods; transplantationDuring the last decade a growing number of centres have become involved in the measurement of the immunosuppressive agent cyclosporin, When the UK Cyclosporin Quality Assessment Scheme (UKCQAS) was started by two of us (DH and AI) in 1984 there were 14 participants in the UK; now there are over 50. The increasing number of indications for which cyclosporin can be prescribed, together with the proliferation of centres capable of performing organ transplantation, suggests that an even larger number of laboratories are likely to offer this assay as a service in the future. The purpose of this review is to summarize current information relating to cyclosporin monitoring and to give some indication of the clinical problems surrounding the use of the results. It has been written against the background of three consensus documents, based on input from laboratory scientists and clinicians, all of which have arrived at similar concluslons.l ? Since these consensus reports were written there have been some changes with regard to the immunoassays available for cyclosporin measurement and there have been a number of reports documenting the performance of the newest assays.The present authors have all been involved in the measurement of cyclosporin in a variety of clinical settings and intend that this review should allow laboratory workers and clinicians to make an informed choice when deciding which method to use for the measurement of cyclosporin. To this end we have drawn upon recent literature, Correspondence: Dr D W Holt. 420 our own experience in this field, data from the UKCQAS, and we have surveyed current practices in UK laboratories performing the measurement.We have chosen to concentrate on three main areas. First, the pharmacology of the drug, since this is essential to an appreciation of the methodological problems associated with cyclosporin measurement. Secondly, we have produced a detailed review of analytical methods and their relative performance. Thirdly, we present a summary of the clinical factors which influence the interpretation of the results in the diverse clinical settings in which cyclosporin is used, to provide those who are producing the cyclosporin results with some insight into the problems faced by those who have to use the data. CYCLOSPORINSince the cyclic peptide cyclosporin (cyclosporin A, ciclosporin, cyclosporine, Sandimmun@) began to be included in immunosuppressive protocols, it has had a profound effect on clinical transplantation world-wide, not only in terms of improved organ and patient survival but also in improving more positive public attitudes towards transplantation. One major disappointment which emerged with the clinical use of cyclosporin was that therapeutic doses in man caused a number of adverse side-effects, in contrast to many of the animal species studied. These sideeffects included renal and hepatic dysfunction, hypertension, neurotoxicity, lymphoma, abnormal glucose homeostasis, hyp...

show abstract

“…Analytical methods for cyclosporine in whole blood include high-performance liquid chromatography (HPLC), fluorescence polarization immunoassay (FPIA), radioimmunoassay (RIA), and enzyme-multiplied immunoassay technique (EMIT) (5)(6)(7)(8)(9). The HPLC method has the advantage of detecting only native cyclosporine and cyclosporine metabolites, but it usually involves time-consuming processes for analysis, and requires special equipment and maintenance.…”

Section: Introductionmentioning

confidence: 99%

Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT^®2000 cyclosporine specific assay with the COBAS MIRA‐plus analyzer

Kimura

Iyama

Yamaguchi

et al. 2001

Clinical Laboratory Analysis

View full text Add to dashboard Cite

We describe the evaluation of the EMIT 2000 cyclosporine specific assay kit, an enzyme-multiplied immunoassay for cyclosporine in whole blood, with a COBAS MIRA-plus analyzer. The enzyme used for the assay was glucose-6-phosphate dehydrogenase (EC 1.1.1.49 G6PDH) from Leuconostoc mesenteroides; the monoclonal antibody is fairly specific for cyclosporine, and is not reactive with most metabolites. The assay principle is based on competitive immunoassay with G6PDH-labeled cyclosporine and cyclosporine in sample to the anticyclosporine mouse monoclonal antibody binding site. The within-assay coefficient of variation (CV) of this method was 2.7-4.2% (n = 10) at the levels of 56.2-339.7 microg/L. Day-to-day CVs ranged from 4.2-8.1% at the levels of 47.2-350.2 microg/L. The within-day CVs ranged from 2.0-6.4% at the levels of 43.3-330.5 microg/L. The functional detection limit was 24.9 microg/L. Samples treated with pretreatment reagent were stable at least 5 hr. Calibration was stable at least 10 days. The analytical recovery was 81-109%. The correlation between values obtained with the EMIT 2000 cyclosporine specific assay kit (y) and fluorescence polarization immunoassay (FPIA) (TDxFLx) (x) was: y = 0.880x - 13.053 microg/L (r = 0.984, Sy/x = 15.968, n = 71) with a mean difference of 31.42 +/- 19.89 microg/L ((TDxFLx - EMIT 2000) +/- SD); for the FPIA (AxSYM) (x): y = 0.989 - 4.144 microg/L (r = 0.981, Sy/x = 17.478, n = 71) with a mean difference of 5.56 +/- 17.38 microg/L ((AxSYM - EMIT 2000) +/- SD); and for the radioimmunoassay (RIA, CYCLO-Trac SP) (x): y = 0.893 - 6.764 microg/L (r = 0.993, Sy/x = 10.582, n = 71) with a mean difference of 22.18 +/- 14.98 microg/L ((RIA - EMIT 2000) +/- SD) using the Bland-Altman technique.

show abstract

Measurement of cyclosporine a by a specific radioimmunoassay with a monoclonal antibody and 125I tracer

Cited by 16 publications

References 25 publications

Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events

Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events

Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force

Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT^®2000 cyclosporine specific assay with the COBAS MIRA‐plus analyzer

Contact Info

Product

Resources

About

Measurement of cyclosporine a by a specific radioimmunoassay with a monoclonal antibody and 125I tracer

Cited by 16 publications

References 25 publications

Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events

Switching from Cyclosporine to Tacrolimus in Patients with Chronic Transplant Dysfunction or Cyclosporine-Induced Adverse Events

Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force

Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT®2000 cyclosporine specific assay with the COBAS MIRA‐plus analyzer

Contact Info

Product

Resources

About

Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT^®2000 cyclosporine specific assay with the COBAS MIRA‐plus analyzer